Almost 200 cancer patients have been left to die in Scotland in the last two years after their last-ditch attempts to get life- extending treatments were rejected by the NHS, campaigners claimed today.
As of now, there exists no path to approval for so called follow-on biologics as there is with small-molecule pharmaceutical products.
Thanks to the hard work of Frank Friedman, long time supporter of the Kidney Cancer Association, the governor of Michigan has proclaimed March as Kidney Cancer Awareness month in the state for the fourth year in a row.
Comparative effectiveness studies that directly compare the risks and benefits of different treatments for a particular condition...have been controversial; the pharmaceutical and medical device industries may not fund them, and some are concerned that the government or insurers may use the results to mandate specific approaches to treatment or to deny coverage.
Dr. David Sachs of Harvard University talks with Joyce Graff about his team's new method for performing a kidney transplant and "training" the recipient's body to "tolerate" the transplanted organ, so that the recipient will not require anti-rejection medications.
President Obama intends to nominate Dr. Margaret A. Hamburg, a former New York City health commissioner, to lead the Food and Drug Administration, sidestepping a battle between drug safety advocates and the drug industry, according to people briefed on the decision.
A new guide from Cleveland Clinic outlines the various approaches to kidney cancer treatment.
Presented by: Keith Skubitz, M.D., professor of Medicine, Hematology, Oncology and Transplantation, Masonic Cancer Center, University of Minnesota Medical School; faculty candidate, James P. Wilmot Cancer Center, Thursday, March 19, 2009, University of Rochester.
Pfizer distributed free doses of the drug to build evidence that it was helping patients.
When the researchers tested human cancer cells for SPOP, they found it in 85 percent of renal cell carcinomas, a common form of kidney cancer.